Antagonists of the bradykinin b1 receptor

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/10 (2006.01) A61K 38/08 (2006.01) A61K 47/48 (2006.01) A61P 29/00 (2006.01) C07K 7/06 (2006.01) C07K 7/08 (2006.01) C07K 7/18 (2006.01)

Patent

CA 2545499

The present invention relates to certain biologically active peptides and conjugated peptides which can be used as therapeutics or prophylactics against diseases or conditions linked to B1 as the causative agent. In a preferred embodiment of the invention biologically active PEG-conjugated peptides are provided. In one aspect of the present invention, pharmacologically active PEG-conjugated peptides of the present invention are useful to treat inflammation or pain.

La présente invention concerne certains peptides actifs biologiquement et des peptides conjugués qui peuvent être utilisés en tant qu'agents thérapeutiques ou prophylactiques dans des maladies ou des troubles liés à B1 comme agent étiologique. Un mode de réalisation préféré de cette invention a trait à des peptides conjugués à PEG actifs biologiquement. Dans un autre aspect de ladite invention, des peptides conjugués à PEG actifs au niveau pharmacologique sont utilisés afin de traiter une inflammation ou une douleur.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Antagonists of the bradykinin b1 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antagonists of the bradykinin b1 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of the bradykinin b1 receptor will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1702800

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.